American Peptide Company to be Acquired by Otsuka Chemical Company
News Aug 04, 2008
American Peptide Company, Inc. has announced that its parent company, Ito Life Sciences, will be acquired by Otsuka Chemical Company, part of the Otsuka Group.
Otsuka Chemical Company will be the new owner of American Peptide Company and Ito Life Sciences Shanghai, both subsidiaries of Ito Life Sciences, beginning September 1, 2008. Ito Life Sciences is currently owned by Itoham Foods.
"American Peptide Company is poised to benefit greatly from this acquisition,” says Takahiro Ogata, president and COO, American Peptide Company.
“By operating as an enterprise of Otsuka Chemical Company, we will create new global networking opportunities as well as channel more financial resources to our production and manufacturing facilities. As a result, we will enhance our Total Peptide Management services to our customers.”
The Total Peptide Management program is a customized service platform that offers a broad array of high-quality peptides, value-added services, and expert consultation.
Leveraging the experience and expertise of the American Peptide Company’s leadership team, the program helps pharmaceutical and biotech customers properly select peptides and follow correct procedures and compliance guidelines from research development through scale-up to full manufacturing.
As American Peptide Company continues to build its technical capabilities and customer base with its service-oriented Total Peptide Management program, it will be a critical asset to the Otsuka Chemical Company portfolio.
Additionally, American Peptide Company is expanding its facilities in Vista and Sunnyvale, California to accommodate large scale peptide production at the kilogram scale for the company’s growing customer network.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE